Original White Feather Rice Intranet
Highlights
Recently, Humanwell Pharmaceutical announced that its holding subsidiary, Yichang Humanwell Pharmaceutical, was approved to add a new 10mg specification of oxycodone hydrochloride sustained-release tablets, and won the first generic version of the product in September 2022, with an approved specification of 40mg. According to data from Minenet, oxycodone hydrochloride sustained-release tablets have maintained a sales scale of 600 million yuan in the terminals of China's public medical institutions in recent years, with a year-on-year increase of 5.53% in 2023.
Oxycodone hydrochloride is a pure opioid receptor agonist that is relatively selective for μ receptors and can be used to relieve persistent moderate to severe pain.
Sales of terminal oxycodone hydrochloride sustained-release tablets in China's public medical institutions in recent years (unit: 100 million yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In recent years, oxycodone hydrochloride sustained-release tablets have maintained a sales scale of 600 million yuan in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), with a year-on-year increase of 5.53% in 2023, and are the TOP8 products of painkillers.
Humanwell Pharmaceutical's approval of oxycodone hydrochloride sustained-release tablets
Source: Minenet China Listed Drugs (MID) Database
According to the data of Minenet, there are 4 companies with production approval for oxycodone hydrochloride sustained-release tablets, and Yichang Renfu Pharmaceutical won the first generic in September 2022, with an approved specification of 40mg, and this time it was approved to add a new 10mg specification. At present, only Southwest Pharmaceutical Co., Ltd. is under review for generic 4 types of production, and it is deemed to have passed the evaluation after approval.
Humanwell Pharma said that the approval of the new specifications of oxycodone hydrochloride sustained-release tablets further enriches the company's product line, meets the clinical needs to a greater extent, and is conducive to enhancing market competitiveness. Up to now, the project has invested about 25 million yuan in research and development.
Humanwell Pharmaceutical's approved products this year
Source: Minenet China Declaration Progress (MED) database
Since the beginning of this year, Humanwell Pharmaceutical's new products have been reported frequently, with 4 products including enzalutamide soft capsules and peony licorice decoction granules approved for marketing, and new indications for remifentanil hydrochloride for injection. Among them, the terminal sales scale of remifentanil hydrochloride for injection in China's public medical institutions will exceed 4 billion yuan in 2023. In addition, 8 products, including riprocaine cream, eicosapentaenoic acid ethyl ester soft capsules, and drospirenone ethinylestradiol tablets, are under review, covering therapeutic subclasses such as anesthetics, lipid modulators, anti-inflammatory drugs, and antirheumatic drugs.
Source: Minenet database, company announcements
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. If there is any omission, please correct it!